President Donald Trump has received a dose of an experimental antibody treatment being developed by the drugmaker Regeneron, in addition to several other drugs, including zinc, vitamin D and a heartburn treatment, according to a letter from his doctor that was released by the White House on Friday.

Trump and the first lady, Melania Trump, announced early Friday that they had tested positive for the coronavirus. The president has a low-grade fever, nasal congestion and a cough, according to two people close to Trump.

In the letter, Trump’s doctor, Dr. Sean Conley, said that “he completed the infusion without incident” and that he “remains fatigued but in good spirits.”

In this undated image from video provided by Regeneron Pharmaceuticals on Friday, Oct. 2, 2020, scientists work with a bioreactor at a company facility in New York state, for efforts on an experimental coronavirus antibody drug. Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help the immune system eliminate it. (Regeneron via AP) NY864 NY864 ( / The Associated Press)
Seattle Times story on local, global push for monoclonal antibody treatment for COVID-19

President Trump and COVID-19

There are no approved treatments for COVID-19, but the Regeneron treatment is one of the most promising candidates, along with another antibody treatment developed by Eli Lilly. Both are being tested in patients around the country. Initial results have suggested that they can reduce the level of the virus in the body and possibly shorten hospital stays — when they are given early in the course of infection.


In an interview Friday, Regeneron’s chief executive, Dr. Leonard Schleifer, said that Trump’s medical staff reached out to the company for permission to use the drug and that it was cleared with the Food and Drug Administration.

“All we can say is that they asked to be able to use it, and we were happy to oblige,” he said. He added that so-called compassionate-use cases — when patients are granted access to an experimental treatment outside of a clinical trial — are decided on a case-by-case basis, and he is not the first patient to be granted permission to use the treatment this way. “When it’s the president of the United States, of course, that gets — obviously — gets our attention.”

Schleifer has known Trump casually for years, having been a member of his golf club in Westchester County.

A spokesperson for Regeneron, Hala Mirza, said that for its coronavirus treatment, “our first priority is to maintain a sufficient supply in order to conduct rigorous clinical trials,” adding, “there is limited product available for compassionate-use requests that are approved under certain exceptional circumstances on a case-by-case basis.”

Eli Lilly also has ties to the Trump administration. Alex Azar, secretary of the Department of Health and Human Services, is a former executive at the company.

Although neither company’s product has been authorized for emergency use by the Food and Drug Administration, companies can grant access to their experimental treatments through what is known as compassionate use — for example, if all other options have failed and a patient might die without trying the drug.


During the pandemic, Trump has promoted a range of unproven or scientifically questionable treatments for the virus and himself took hydroxychloroquine in the hopes that it could prevent infection. The FDA authorized hydroxychloroquine for emergency use this spring, then revoked its approval after concluding that the drug’s potential benefits did not outweigh the risks.

Trump has also enthusiastically endorsed the use of convalescent plasma and pushed for the FDA to authorize the treatment for emergency use even though there is still not good evidence that it works. He suggested that injecting a disinfectant like bleach could help combat the virus, although later said he was joking.

Other treatments — an inexpensive steroid, dexamethasone, and remdesivir, an antiviral drug developed by Gilead — have been shown in clinical trials to help patients with COVID-19 who are sick enough to be hospitalized. Neither drug has gone through the rigorous FDA approval process to determine that it is safe and effective, although dexamethasone is widely available for other uses, and remdesivir has received emergency authorization.

Conley said in his letter that in addition to the Regeneron treatment, Trump was also taking zinc, vitamin D, melatonin, a daily aspirin and famotidine, the generic name for the heartburn drug Pepcid. Some of these products, which are widely available, have been studied as treatments for COVID-19, although none have been definitively proven to work.

Trump in 2018 signed the Right to Try law, which allows patients and their doctors to directly request an experimental treatment from a company, without first seeking approval from the FDA, which typically approves the vast majority of such requests. The Right to Try law is rarely used, however, with most doctors and hospitals preferring to use the existing process of seeking agency approval.

Some ethics experts said it was not surprising that Trump was given an experimental drug, given that it has passed safety trials.


“Presidential medicine is and has been unique,” said Arthur Caplan, a professor of medical ethics at the NYU Grossman School of Medicine. “If his doctors think an intervention might be helpful, and if that judgment is confirmed by outside experts they talk to, and if things look dire or serious, then the president will get access to any and all agents.”

Other experts said that drug companies like Regeneron must now be prepared for what could be a flood of requests from the public.

“One would anticipate that providing access to the president of the United States would lead to significant requests for that experimental treatment by people who are in the same or in potentially worse medical conditions or states,” said Kenneth Moch, a senior adviser at the Global Health Crisis Coordination Center in Atlanta.

In 2014, Moch came under intense criticism after the company where he was chief executive, Chimerix, initially refused to provide an experimental treatment to a 7-year-old boy who was close to dying from a viral infection. After a social media campaign, the company started a new clinical trial that allowed the boy to get the treatment.

Regeneron and Eli Lilly are the furthest along of several companies and teams of researchers in developing what are known as monoclonal antibodies to fight COVID-19. Researchers identify powerful antibodies that fight infection, then manufacture them in large quantities. They are then given to sick patients or to people who have been exposed to the virus, in the hopes that they will help boost the body’s immune response.

Antibody treatments have shown promise against other viruses, including Ebola. On Tuesday, Regeneron said that its treatment, a mixture of two antibodies, hastened recovery time and reduced the amount of virus in the nasal cavities of a small number of volunteers in its ongoing study.


The new results were from a study of 275 volunteers who were treated after being diagnosed with COVID-19. Some received one infusion of the drug while others were given a placebo. Those who were not making their own antibodies at the start of the trial benefited the most, Regeneron reported. Their symptoms resolved in an average of six to eight days, compared with 13 days in those who received the placebo.

The dose that Trump received is the higher of two doses that Regeneron is testing in its trial of outpatients with COVID-19.

In September, Eli Lilly reported that a single infusion of its monoclonal antibody markedly reduced levels of the coronavirus in newly infected patients and lowered the chances that they would need hospitalization.

Despite their early promise, monoclonal antibodies are difficult and expensive to manufacture, and some have raised questions about whether the companies will be able to make enough to meet global demand if they are proven to work.

Regeneron has been awarded more than $500 million from the federal government to develop and manufacture its product before the clinical trials have concluded. In August, the company announced it was teaming up with a larger company, Roche, to ramp up production.